Lanib 250mg (Lapatinib) tablets are classified as anti-cancer agent, which is orally active drug used for treating breast cancer. Chemically classified as quinazoline with strong anti-cancer effect and the tablet Lanib is a synthetic oral tablet.
PRODUCT DETAILS
Brand Name : Lanib
Composition : Lapatinib
Strength availability : 250mg
Manufactured by : BDR
Pack : 120 tablets
Liver damage:
Raising level of AST, ALT or bilirubin may cause liver injury
To inhibits this condition, periodic LFT should be control
Diarrhea:
Serious diarrhea may cause to dehydration leads death also; if patient do not recover from this severity must stop with this therapy.
Interstitial lung disease:
Patient should be check with pulmonary symptoms and give supportive measures.
On Serious condition, treatment should be discontinuing
QT prolongation:
Balance ECG periodically
Give the patient substituent for this adverse condition
Hypokalemia and hypomagnesemia correction should be takes place
Cutaneous reactions:
Some life-threatening reactions may occur, in this condition therapy should be discontinued
Embryo fetal damage:
Lanib leads to fetal damage and produce some deformities.
During therapy Patient should advice not getting pregnant.
Hertab 250mg (Lapatinib) tablets are classified as anti-cancer agent, which is orally active drug used for treating breast cancer, Chemically classified as quinazoline with strong anti-cancer effect and the tablet.
Hertab tablets are classified as anti-cancer agent, which is orally active drug used for treating breast cancer.
Chemically classified as quinazoline with strong anti-cancer effect and the tablet Hertab is a synthetic oral tablet.
Normally targeted therapy or tyrosine kinase inhibitor drugs can increase the plasma amino transferase levels which may leads to liver injury.
Hertab tablets are classified as;
Tyrosine kinase prohibitor
Stop the HER2/neu & epidermal growth factor receptor activity
Targeted therapy
Signal transduction prohibitor
PRODUCT DETAILS
Brand Name : Hertab
Composition : Lapatinib
Strength availability : 250mg
Manufactured by : Hetero
Pack : 150 tablets
Liver damage:
Raising level of AST, ALT or bilirubin may cause liver injury
To inhibits this condition, periodic LFT should be control
Diarrhea:
Serious diarrhea may cause to dehydration leads death also; if patient do not recover from this severity must stop with this therapy.
Interstitial lung disease:
Patient should be check with pulmonary symptoms and give supportive measures.
On Serious condition, treatment should be discontinuing
QT prolongation:
Balance ECG periodically
Give the patient substituent for this adverse condition
Hypokalemia and hypomagnesemia correction should be takes place
Cutaneous reactions:
Some life-threatening reactions may occur, in this condition therapy should be discontinued
Embryo fetal damage:
Hertab leads to fetal damage and produce some deformities.
During therapy Patient should advice not getting pregnant.
Azel is a hormonal therapy, for men who are all affected with prostate carcinoma in metastaic stage. Azel 40mg Capsules are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non steroidal anti-androgen medication. Azel 40mg is involved in association with castration in the therapy of metastatic or long lasting castration resistant prostate cancer. Azel 40mg is a prescription medicine, the main ingredient which is used as enzalutamide, only prescribed by medical oncologist.
Bdenza is a hormonal therapy, for men who are all affected with prostate carcinoma in metastatic stage. Bdenza 40mg capsules are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non steroidal anti-androgen medication. Bdenza 40mg is involved in association with castration in the therapy of metastatic or long lasting castration resistant prostate cancer. Bdenza 40mg is a prescription medicine, the main ingredient which is used as enzalutamide, only prescribed by medical oncologist.